Breaking AI & Tech News Analyzed

Donald Trump has repeatedly framed inflation as a "hoax" and declared that he has "won affordability," yet independent analyses reveal that his touted initiatives deliver only marginal relief for most Americans.One of his most publicized programs, the TrumpRX prescription‑drug platform, lists just 61 medications out of the thousands needed nationwide. Moreover, price comparisons show that a medium dose of Wegovy costs $349 on TrumpRX, while the same dose sells for $163 in Japan and $198 in Germany. Similar gaps appear for diabetes drug Xigduo and autoimmune medication Xeljanz, which are significantly cheaper abroad.The website markets itself as a solution for uninsured, cash‑paying patients, but it does nothing for the roughly 85 % of Americans who already have prescription coverage.On housing, Trump’s executive order banning Wall Street firms from buying single‑family homes is unlikely to move the needle. Institutional investors own only about 2 % of such homes, while the nation faces a shortage of roughly 4.7 million units, according to Zillow. The ongoing war in Iran has also pushed mortgage rates higher, further straining affordability.Gasoline prices have surged since the Iran conflict began, climbing to an average of $4.10 per gallon – a 37 % increase from the pre‑war level of $2.98.Food costs tell a similar story. The Consumer Price Index shows a 3.1 % rise in overall food prices from February 2025 to February 2026, with coffee up 18.4 %, beef up 14.4 %, and fresh vegetables up 5.4 %. Tariffs championed by the administration have contributed to these hikes.International bodies echo domestic concerns. The OECD projects U.S. inflation to exceed 4 % this year, largely driven by the Iran war, a level higher than the 3 % rate recorded at the end of the Biden administration.Trump also claims to have eliminated taxes on overtime and Social Security benefits. In reality, overtime earnings are still subject to federal income tax on the base wage and to full Social Security and Medicare payroll taxes. Only the overtime premium enjoys a partial tax break. Likewise, more than half of Social Security recipients will continue to owe income tax on their benefits, contradicting the administration’s “no‑tax” narrative.Other initiatives, such as the “Trump Accounts” child‑savings program, provide a one‑time $1,000 seed deposit and allow families to contribute up to $5,000 annually. While beneficial for affluent households, the scheme offers limited assistance to families living paycheck‑to‑paycheck.Policy decisions have also raised costs for vulnerable groups. By opposing extensions of Obamacare subsidies, average health‑care premiums have risen by over 20 % for more than 20 million people. Simultaneously, proposed cuts to LIHEAP threaten heating and cooling assistance for roughly 6 million low‑income households.In sum, Trump’s affordability rhetoric serves more as political branding than substantive economic relief. The modest scope of his programs and the persistence of rising prices suggest that most working‑class Americans will see little improvement in their day‑to‑day expenses.

Peptides are short chains of amino acids that naturally occur in the body, acting as hormones such as insulin, oxytocin and vasopressin, or as fragments released during protein digestion.In recent years, a wave of interest has turned these molecules into purported therapeutic agents for everything from weight loss to anti‑ageing and tissue repair. Prescription drugs like semaglutide (Wegovy) and tirzepatide (Mounjaro) are synthetic peptides that have undergone rigorous clinical testing and are approved for specific medical uses.However, a large portion of the market consists of unregulated, experimental peptides sold for self‑administration. These products often bypass the strict approval processes required for medicines, raising serious safety concerns.Who is using these products? Initially confined to a niche of powerlifters and bodybuilders in the 2010s, the audience has expanded dramatically. Influential figures such as podcaster Joe Rogan have promoted combinations like the “Wolverine stack” (BPC‑157 and TB‑500) for injury recovery, while other compounds—CJC‑1295, MK‑677, ipamorelin, and GHK‑Cu—are marketed for muscle growth and anti‑ageing. Social media platforms are now flooded with instructions on purchasing and injecting these substances.Scientific backing is scant. Reviews of the literature reveal that most experimental peptides have only been tested in animal or cell models. For example, BPC‑157 shows promise for tendon and muscle repair in pre‑clinical studies, but no randomized human trials have validated these effects. Similarly, TB‑4 and its synthetic analogue TB‑500 have demonstrated limited blood‑vessel formation in laboratory settings, yet human data are absent and both are listed as prohibited substances by the World Anti‑Doping Agency.Researchers also highlight a critical knowledge gap: dosage, frequency and treatment duration remain undefined, making self‑administration a gamble.Legal landscape in the UK is clear that peptides not classified as medicines fall outside the Medicines and Healthcare products Regulatory Agency’s (MHRA) remit. If a seller makes medicinal claims, the product must hold a marketing authorisation under the Human Medicines Regulations 2012. The MHRA warns that labeling items as “research use only” does not shield vendors from enforcement when evidence shows the products are intended for human consumption.Health risks are multi‑fold. Experts caution that benefits observed in animal studies do not guarantee safety in humans. Contamination with harmful impurities or bacterial endotoxins can trigger severe reactions, including septic shock. Injecting excess natural peptides may disrupt the body’s tightly regulated hormonal balance, potentially affecting multiple physiological pathways.There is also theoretical concern that augmenting peptide levels could accelerate tumour growth, as some cancers over‑express certain peptide pathways. While no direct cases have been documented, the possibility underscores the need for caution.Additional dangers include improper injection techniques (e.g., air embolism), unknown interactions with existing medications, and the lack of systematic monitoring of long‑term effects. As one researcher put it, “If something goes wrong, users may never notice until irreversible damage has occurred.”

The United States has long honored past presidents by naming airports, dams and monuments after them, but President Donald Trump is pushing the practice to an extreme, seeking to become the most commemorated leader in American history. Less than a year and a half into his second term, Trump’s brand has proliferated across government buildings, federal agencies and even consumer platforms. In February, the administration unveiled TrumpRx, a prescription‑drug website that listed only 43 medications—most of which are available as cheaper generics elsewhere—yet proudly displayed the former president’s signature and logo. Just weeks later, the White House and the U.S. Navy announced a new "Trump class" of battleships, billed as the "largest ever built." A Pentagon release noted that the Navy has not used battleships in combat for 35 years, suggesting the project is more a vanity exercise than a strategic necessity. Federal institutions have not been spared. In December 2025 the U.S. Institute of Peace was renamed the "Donald J. Trump United States Institute of Peace," a move the White House framed as a reminder of "strong leadership" for global stability—just weeks before the administration launched a military strike on Iran. Trump’s influence extended to the arts when, in February 2025, he appointed a new board to the John F. Kennedy Center for the Performing Arts and installed himself as chair. The board voted in December to rename the venue the "Donald J. Trump and John F. Kennedy Center," a change that immediately faced a legal challenge. Republican lawmakers have largely embraced the naming spree. One congressman introduced legislation to carve Trump’s likeness onto Mount Rushmore, while another proposed naming a major airport after him, underscoring the party’s willingness to reward the president’s personal brand. Political scientist Steven Levitsky of Harvard warned that Trump operates "unconstrained" by advisers or party elders, noting that today’s Republican ambition often hinges on pleasing the president, including attaching his name to public projects. Visual propaganda has also surged. Giant banners bearing Trump’s image now hang from the Department of Justice and the Department of Labor buildings, a rarity for a sitting president and a practice more typical of authoritarian regimes, according to Princeton sociologist Kim L. Scheppele. Beyond buildings, the administration has pursued numismatic honors. A 24‑karat gold coin featuring Trump standing over a desk was approved by a hand‑picked arts commission, and drafts of a new $1 coin displayed an air‑brushed profile of the former president. The Treasury Department announced that Trump’s signature will appear on U.S. paper currency later this year, a move Treasury Secretary Scott Bessent described as a "powerful way to recognize historic achievements" of the nation. Critics argue that the public does not share the president’s enthusiasm. The 2026 National Parks Pass, which traditionally showcases natural scenery, sparked outrage when a draft featured Trump’s stern face with a spectral George Washington behind him. A cottage industry of stickers emerged to cover the image, forcing the National Park Service to warn that such alterations could void the pass. White House spokesperson Davis Ingle defended the branding, claiming it reflects Trump’s “vast accomplishments,” including the largest tax cut in history and border security measures. Yet scholars and opponents contend that the relentless self‑promotion blurs the line between public service and personal aggrandizement. As the branding campaign continues, legal challenges, public pushback, and questions about fiscal priorities suggest that Trump’s quest to name everything after himself may soon encounter more than just decorative resistance.

American consumers are watching gasoline and airline fares climb, while economists warn that the war in Iran will keep pressure on prices across the U.S. economy.“The good old days are gone,” said Christopher Tang, a professor at UCLA’s Anderson School of Management who studies global supply chains. “We see gasoline prices rising now, but that’s only the tip of the iceberg; everything will become more expensive.”Since the conflict began in late February, crude oil has surged past $110 a barrel. The rally is tied to Iran’s leverage over the Strait of Hormuz, a narrow chokepoint through which roughly 20% of the world’s oil passes.In a recent address, President Donald Trump claimed the United States is “totally independent of the Middle East” and has “plenty of gas.” However, Brookings Institute’s energy‑security director Samantha Gross reminded listeners that oil is a globally traded commodity and the U.S. still imports significant volumes, meaning American consumers will face the same high prices as the rest of the world.Iran has either halted shipments through the strait or imposed a toll of up to $2 million per vessel. Tankers are forced to take longer routes or pay the fee, inflating logistics costs for all downstream users.Major logistics players are already passing those costs on. Amazon announced a 3.5% surcharge for third‑party sellers, while UPS and FedEx have introduced fuel surcharges exceeding 25%. The United States Postal Service will add an 8% surcharge to transportation rates starting 27 April, noting the charge is “less than one‑third of what our competitors charge for fuel alone.”When the prices go up, they rarely come back down— Christopher Tang, UCLACountries have dipped into strategic oil reserves to blunt the shock, but economists such as Virginia Tech’s David Bieri warn that refilling those stockpiles will require buying oil at today’s elevated prices, keeping the upward pressure on the market.Higher oil costs ripple beyond fuel. Crude is a key feedstock for chemicals, pharmaceuticals and fertilizers, meaning the surge could translate into higher prices for prescription drugs and groceries.Cornell University’s agricultural economics professor Christopher Wolf explained that diesel, a major input for farm equipment and fertilizer production, is also climbing, raising the cost of both crop cultivation and livestock raising.Retailers and food processors are already adjusting. “If we anticipate higher costs, we start raising prices early to avoid a sudden shock later,” Wolf said, describing a “rational expectations” approach.The Independent Grocers Alliance warned that a 10‑15% rise in fuel costs could lift food prices by 2‑4% by mid‑summer, underscoring the broader impact on household budgets.Although President Trump expects the United States to exit the Iran conflict within two to three weeks, experts agree that even a swift resolution will not instantly reverse the price spikes.The strait’s strategic importance means the political risk premium on oil will linger. “You never know when this could flare up again,” said Northeastern University’s Ravi Ramamurti, adding that the effect is likely to be persistent.As Tang summed up, “When the prices go up, they rarely come back down.”

Cuba’s government declared a humanitarian amnesty for 2,010 prisoners ahead of Easter’s Holy Week, a decision it says follows a careful review of each inmate’s conduct, health, and time served. The announcement, made by state media on Thursday, represents the second such amnesty this year and the fifth large‑scale pardon since 2011, bringing the total to more than 11,000 released individuals. While Havana officially denies acting under U.S. pressure, the timing aligns with what analysts describe as the most aggressive Washington campaign against the island in decades. The move comes a day after Cuba’s top diplomat in Washington invited the United States to assist in overhauling the island’s “crippled” economy, part of ongoing talks that have yet to produce concrete outcomes. U.S. officials, including President Trump’s administration, have repeatedly called for a change of government in the communist‑run state, with the president even musing about “taking” the island. Yet recent diplomatic exchanges suggest a nuanced shift: both sides have held talks, and scholars note that the amnesty could be a tangible sign of progress, however modest. University of Miami Cuban‑studies chair Michael Bustamante told AFP, “It seems not far‑fetched to think that this is a sign that some of the conversation between both governments is advancing… To where? Unclear.” He added that the political significance will depend on the profile of those released. The Cuban presidency did not disclose the names or crimes of the pardoned individuals, but indicated the group includes young people, women, and inmates over 60 who are slated for early release within the next six to twelve months. Foreign nationals and Cuban expatriates are also among those granted clemency. Importantly, the amnesty excludes anyone convicted of murder, sexual assault, drug‑related offenses, theft, illegal livestock slaughter, or crimes against state authority. Earlier in March, the government freed 51 prisoners as a “good‑will” gesture toward the Vatican, which often mediates between Washington and Havana. The current pardon is framed as part of the “humanitarian legacy of the Revolution” and is presented as customary practice during Holy Week. The release coincides with Russia’s announcement of a second oil tanker bound for Cuba, following a recent easing of the U.S. oil blockade that allowed the first shipment. Bustamante speculated that the timing may not be coincidental, suggesting a possible link between U.S. policy shifts and Cuba’s diplomatic overtures. U.S. Secretary of State Marco Rubio, a Cuban‑American critic of Havana, reiterated on Fox News that Cuba’s economic woes cannot be solved without political reform, warning that the island faces “a lot of trouble.”

President Donald Trump has taken a significant step to push for pharmaceutical deals by signing an executive order that could impose tariffs of up to 100% on some patented drugs. This move is part of his administration's effort to secure lower prices for medicines.Under the executive order, companies that have signed a 'most favoured nation' pricing deal and are actively building facilities in the US will have a zero-percent tariff. For those that don't have a pricing deal but are building such projects in the US, a 20 percent tariff will apply, but it will increase to 100 percent in four years.A senior administration official stated that companies still have months to negotiate before the 100 percent tariffs kick in. Bigger companies will have 120 days, and 180 days are offered for everyone else.The administration has already reached 17 pricing deals with major drugmakers, 13 of which have signed. The executive order aims to address the threatened impairment of national security posed by imports of pharmaceuticals and pharmaceutical ingredients.Critics, pharmaceutical leaders, and medical groups have warned of the consequences the new tariffs could bring, including increased costs and potential jeopardy to billions in US investments. The pharmaceutical company trade group PhRMA has expressed concerns that taxes on cutting-edge medicines will increase costs and could jeopardize investments.

French authorities detained European Parliament member Rima Hassan on Thursday, accusing her of "apology for terrorism" after a social‑media post referenced Kozo Okamoto, a participant in the 1972 Ben Gurion Airport attack. The detention, reported by Le Parisien, marks a rare instance where a sitting MEP’s parliamentary immunity appears to have been set aside. According to the newspaper, Hassan had already removed the contentious post from X, but the investigation continued. Police also reported finding a small quantity of synthetic drugs in her possession during the arrest. Jean‑Luc Mélenchon, founder of the left‑wing La France Insoumise (LFI) party, condemned the move on X, stating, "There is no longer parliamentary immunity in France. Intolerable." He and other LFI colleagues argue the action is designed to silence supporters of Palestine. LFI parliamentarians Sophia Chikirou and Mathilde Panot echoed the criticism, accusing the French police and justice system of being weaponised against activists. Panot warned that President Emmanuel Macron’s France is witnessing a "new level" of criminalisation of political opponents. The controversy follows Hassan’s recent denial of entry to Canada, which she described as censorship, and a prior alert by far‑right National Rally politician Matthias Renault to Paris prosecutors about the same X post. Renault welcomed the detention, calling it "the beginning of the end of impunity for the LFI MP." Hassan, a 33‑year‑old French‑Palestinian lawyer elected to the European Parliament in 2024, is a vocal critic of Israel’s war in Gaza and participated in a Gaza‑bound flotilla intercepted by Israeli forces in October 2025. Her advocacy has repeatedly drawn ire from pro‑Israel groups across Europe. While Hassan and her legal team have not responded to Reuters’ requests for comment, the incident raises broader questions about the balance between anti‑terrorism legislation and political freedoms within the EU, especially as debates over Palestine intensify across the continent.

President Donald Trump has announced a new policy threatening to impose 100% tariffs on US pharmaceutical companies that do not agree to lower their drug prices. This move is part of his effort to address the high cost of prescription medications in the US.The tariffs will specifically target branded drugs and their active ingredients, while generic drugs, which account for over 90% of medicines sold in the US, will be exempt for at least one year. Additionally, certain specialty drugs, such as orphan, veterinary, and other specialty drugs, will be exempt if they are from countries with which the US has a trade deal or meet urgent public health needs.Drugmakers that enter into pricing agreements with the White House and onshore drug production will be exempt from the tariffs. Companies planning to increase their domestic manufacturing will face a 20% tariff that will escalate to 100% over four years.The policy has been met with criticism from industry groups, such as the Midsized Biotech Alliance of America (MBAA), which argues that it creates an "unfair two-tiered system" that benefits large companies with diversified portfolios.Trump has been under pressure to lower drug prices, with US patients often paying nearly triple what patients pay in other developed nations. The announcement comes as the White House faces pressure from consumers to address rising costs amid other tariff-related price increases and high gas prices triggered by geopolitical tensions.

The U.S. Food and Drug Administration announced on Wednesday that it has granted expedited approval to Eli Lilly’s oral weight‑loss medication, orforglipron—marketed under the brand name Foundayo. This makes Foundayo the second GLP‑1 pill to reach U.S. consumers, following Novo Nordisk’s Wegovy tablet approved in December. Orforglipron works by mimicking a natural hormone that regulates appetite and satiety, offering a non‑injectable alternative to existing GLP‑1 injectables. David A. Ricks, Eli Lilly’s chair and CEO, highlighted that fewer than one in ten eligible patients are currently using GLP‑1 therapies, citing barriers such as cost, stigma, and perceived complexity. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken anytime of day regardless of meals, simplifying dosing schedules. Patients will start on a low dose that is gradually increased to mitigate side‑effects. Pricing is projected at $149 per month for the initial dose, with higher‑strength formulations potentially reaching $349 monthly. While private‑insurance coverage remains uncertain, a Trump‑administration proposal could allow Medicare to cover certain patients as early as this summer, with copayments as low as $50 per month. Distribution will commence on Monday through LillyDirect’s direct‑to‑consumer channel, with broader availability in pharmacies and telehealth platforms expected shortly thereafter. The convenience of a once‑daily pill is anticipated to improve adherence, especially for individuals who avoid injectables due to needle aversion or rigid dosing requirements. The approval follows a fast‑track submission submitted only months ago, positioning Foundayo to enter the market roughly three months after Wegovy. This rapid rollout is set to intensify competition in the burgeoning GLP‑1 space, where new agents are continually emerging with claims of better efficacy and lower costs.